Revelation Biosciences, Inc.
REVBAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Roth MKM | maintain | Buy | Feb 13, 2023 |
| Roth Capital | maintain | Buy | Feb 17, 2022 |
Earnings History
Next report: Apr 1, 2027 · EPS est. $-5.99| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-5.92 | $-6.16 | — | — |
| Aug 7, 2026 | $-6.09 | $-6.13 | — | — |
| May 7, 2026 | $-2.71 | $-8.05 | — | — |
| Mar 5, 2026 | $-1.65 | $-9.87 | — | — |
| Nov 7, 2025 | $-7.08 | $-9.38 | — | — |
| Aug 8, 2025 | $-28.04 | $-31.22 | — | — |
| May 9, 2025 | $-25.32 | $-48.16 | — | — |
| Mar 20, 2025 | $-59.76 | $-4.83 | — | — |
News
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three and nine months ended September 30, 2026. Corporate Highlights Released results of an independent market assessment that showed a potential $94 billion total addressable market for Gemini Announced that it has selected a f…
[url="]Revelation Biosciences, Inc.[/url] (NASDAQ: REVB) (the âCompanyâ or âRevelationâ), a clinical-stage life sciences company developing innovative s
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, announced today that, on October 20, 2026, the Company will implement a 1-for-7 reverse split of its common stock. The reverse stock split will be effective as of the morning of October 20, 2026, and the Company's common stock will trade on a post-split basis at the beginn…
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that it has selected Avance Clinical, a full-service contract research organization (CRO) with global operations, to serve as the CRO for its Phase 2/3 adaptive-design TITAN study for evaluating Gemini in patients with acute kidney injury (AKI). The importa…